fda bpc 157 category 2 compounding list
fda bpc 157 category 2 compounding list BPC-157 Approval Status 2026: Clinical Trials The FDA's Category 2 list
The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law FDA's Overreach on Compounded Peptides
USD20.88
USD43.88
Pay in 4 interest-free payments of $5.22 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
